| Product Code: ETC7655384 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Mantle Cell Lymphoma Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Mantle Cell Lymphoma Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Mantle Cell Lymphoma Market - Industry Life Cycle |
3.4 Israel Mantle Cell Lymphoma Market - Porter's Five Forces |
3.5 Israel Mantle Cell Lymphoma Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
4 Israel Mantle Cell Lymphoma Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence and incidence of mantle cell lymphoma in Israel |
4.2.2 Advancements in diagnostic technologies and treatment options for mantle cell lymphoma |
4.2.3 Growing awareness and focus on personalized medicine and targeted therapies in oncology |
4.3 Market Restraints |
4.3.1 High cost associated with novel treatments for mantle cell lymphoma |
4.3.2 Limited access to specialized healthcare facilities and expertise for managing mantle cell lymphoma cases in Israel |
5 Israel Mantle Cell Lymphoma Market Trends |
6 Israel Mantle Cell Lymphoma Market, By Types |
6.1 Israel Mantle Cell Lymphoma Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Revlimid (Lenalidomide), 2021- 2031F |
6.1.4 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Tecartus (Brexucabtagene autoleucel), 2021- 2031F |
6.1.5 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Brukinsa (Zanubrutinib), 2021- 2031F |
6.1.6 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Imbruvica (Ibrutinib), 2021- 2031F |
6.1.7 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Calquence (Acalabrutinib), 2021- 2031F |
6.1.8 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Abemaciclib, 2021- 2031F |
6.1.9 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Elimusertib, 2021- 2031F |
6.1.10 Israel Mantle Cell Lymphoma Market Revenues & Volume, By Elimusertib, 2021- 2031F |
7 Israel Mantle Cell Lymphoma Market Import-Export Trade Statistics |
7.1 Israel Mantle Cell Lymphoma Market Export to Major Countries |
7.2 Israel Mantle Cell Lymphoma Market Imports from Major Countries |
8 Israel Mantle Cell Lymphoma Market Key Performance Indicators |
8.1 Average time from diagnosis to initiation of treatment for mantle cell lymphoma patients in Israel |
8.2 Percentage of mantle cell lymphoma patients receiving targeted therapies or personalized medicine |
8.3 Survival rates of mantle cell lymphoma patients in Israel |
8.4 Number of clinical trials focused on mantle cell lymphoma treatments conducted in Israel |
8.5 Adoption rate of new treatment guidelines for mantle cell lymphoma in Israeli healthcare institutions |
9 Israel Mantle Cell Lymphoma Market - Opportunity Assessment |
9.1 Israel Mantle Cell Lymphoma Market Opportunity Assessment, By Drugs, 2021 & 2031F |
10 Israel Mantle Cell Lymphoma Market - Competitive Landscape |
10.1 Israel Mantle Cell Lymphoma Market Revenue Share, By Companies, 2024 |
10.2 Israel Mantle Cell Lymphoma Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here